Integrum moves into new head office at GoCo Health Innovation Cit

Mölndal, Sweden – May 3, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has moved into its new office at the GoCo House, in the center of GoCo Health Innovation City, as the company continues its expansion.

Integrum has expanded its global corporate headquarters and moved into the new life science district in Gothenburg – the GoCo Health Innovation City. The life science district cover over 200 000 square meters in Mölndal, Gothenburg. The area consists of newly developed offices and facilities, with the aim of promoting knowledge exchange, business collaboration, and world-class innovation in life science and health care.

“Our new location gives us additional space and capacity in an inspirational setting. Our presence in GoCo Health Innovation City also makes us an even more attractive employer to the best minds in the field, which is great for our continued growth as a company and consolidates our position as the global leader in osseointegration,” comments Rickard Brånemark, CEO and founder of Integrum.

Integrum’s new head office address is: Gemenskapens gata 9, SE 431 53 Mölndal, Sweden.  

For more information please contact:

Rickard Brånemark, CEO

Phone: +46 (0) 70 846 10 61

E-mail: rickard.branemark@integrum.se

Certified Adviser

Erik Penser Bank is Certified Adviser and can be reached at +46 (0) 8-463 8000.

ABOUT INTEGRUM

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.